Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Jun;123(6):2357-60.
doi: 10.1172/JCI69684.

Human C3 glomerulopathy provides unique insights into complement factor H-related protein function

V Michael Holers  1
Affiliations
Comment

Human C3 glomerulopathy provides unique insights into complement factor H-related protein function

V Michael Holers. J Clin Invest. 2013 Jun.

Abstract

The study in this issue of the JCI by Tortajada et al. demonstrates that a duplication within the gene complement factor H–related 1 (CFHR1; encoding FHR1) leads to the production of an aberrant larger form of the protein. Elegant in vitro studies of the mutant and normal variants demonstrate an unexpected mechanism of action of FHR1, wherein homodimeration and hetero- oligomerization with FHR2 and FHR5 generates more avid molecules that very effectively compete with FH binding to surfaces and impair its ability to regulate local complement activation. As variants of FHRs are linked to many human inflammatory and autoimmune diseases, these and other recently published structure/function studies of these proteins provide key insights into their complement regulatory activities and likely roles in disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Postulated roles for FHRs based on the current reports discussed herein (8, 18) as well as previous studies (reviewed in refs.
9, 10, 12). Deregulation is manifest by FHR1, FHR2, and FHR5 when these oligomerize and compete with FH for C3b binding. Activities of FHR3 and FHR4A/B are less well defined, but may vary by the context in which they are used. Green color of the C-terminal 2 SCR domains of the FHRs indicates a very high degree of sequence similarity (>90%) with FH SCR19–SCR20. Other domains exhibit lower degrees of homology with FH, but three of the family members (FHR1, FHR2, and FHR5) exhibit conserved dimerization domains (18). The FH regulatory complex model is based on data reported and summarized elsewhere (21): the primary interaction with C3b requires SCR19, and the interaction with GAG occurs within SCR20.
See this image and copyright information in PMC

Comment on

  • C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.
    Tortajada A, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, Alba-Domínguez M, Malik TH, Bedoya R, Cabrera Pérez R, López Trascasa M, Pickering MC, Harris CL, Sánchez-Corral P, Llorca O, Rodríguez de Córdoba S. Tortajada A, et al. J Clin Invest. 2013 Jun;123(6):2434-46. doi: 10.1172/JCI68280. J Clin Invest. 2013. PMID: 23728178 Free PMC article.

Similar articles

See all similar articles

Cited by

References

    1. Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol. Rev. 2008;223:300–316. doi: 10.1111/j.1600-065X.2008.00641.x. - DOI - PubMed
    1. Ricklin D, Lambris JD. Progress and trends in complement therapeutics. Adv Exp Med Biol. 2013;735:1–22. - PMC - PubMed
    1. Varga L, Farkas H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol. 2011;7(2):143–153. doi: 10.1586/eci.11.5. - DOI - PubMed
    1. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256–1264. doi: 10.1038/nbt1344. - DOI - PubMed
    1. Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013;61(2):289–299. doi: 10.1053/j.ajkd.2012.07.028. - DOI - PubMed

Substances

  NODES
twitter 2